March 26, 2018 / 12:15 PM / 4 months ago

BRIEF-Seattle Genetics And Astellas Receive FDA Breakthrough Therapy Designation For Enfortumab Vedotin

March 26 (Reuters) - Seattle Genetics Inc:

* SEATTLE GENETICS AND ASTELLAS RECEIVE FDA BREAKTHROUGH THERAPY DESIGNATION FOR ENFORTUMAB VEDOTIN IN LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER

* SEATTLE GENETICS INC - COS ARE ALSO EVALUATING ENFORTUMAB VEDOTIN IN OTHER SOLID TUMORS, INCLUDING OVARIAN AND NON-SMALL CELL LUNG CARCINOMA Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below